Candel Therapeutics, Inc. CADL 深 沪
已收盘 05-08 16:00:00 美东时间
8.35
+0.560
+7.19%
华盛通- 最 高8.36
- 今 开7.875
- 成交量 253.12万股
- 最 低 7.77
- 昨 收 7.79
- 总市值 6.12亿
- 52周最高 8.36
- 市盈率 静 --
- 换手率 3.45%
- 52周最低 4.35
- 委 比 -86.34%
- 总股本 7327.02万
- 历史最高 14.78
- 量 比 1.15
- 振 幅 7.57%
- 历史最低 0.66
- 每 手 1
- 风险率 0.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Candel Therapeutics To Hold Conference Call On May 15 To Discuss Extended Follow-Up Data From Its Phase 3 Clinical Study Of Aglatimagene Besadenovec In Participants With Intermediate- To High-Risk Localized Prostate Cancer
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced
05-04 20:17
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating
Cantor Fitzgerald initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Overweight rating.
04-20 23:08
10 Health Care Stocks Moving In Friday's Intraday Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 40.5% to $8.25 dur...
04-18 01:05
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Non-Small Cell Lung Cancer Treatment
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene
03-17 20:12
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Candel Therapeutics Q4 EPS $(0.54) Misses $(0.24) Estimate
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.24) by 120.41 percent. This is a 35 percent decrease over losses of $(0.40) per share
03-12 20:25
Candel Therapeutics To Present New Data From Phase 3 Clinical Trial Of Aglatimagene Besadenovec In Patients With Intermediate- To High-Risk Localized Prostate Cancer At AUA 2026 Annual Meeting Plenary Program
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that
03-09 20:17
Akamai Technologies, Inseego, Ardelyx And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around...
02-20 21:03
Why Is Candel Therapeutics Stock Falling Friday?
Candel Therapeutics stock down on public offering pricing, intends to use proceeds for cancer therapies and development costs.
02-20 18:55
